NEWARK, Del, March 20, 2024 (GLOBE NEWSWIRE) -- The global KRAS inhibitor market was valued at US$ 108 million in 2023 and is anticipated to attain a valuation of US$ 196 million by 2034. The market is likely to develop at a 5.5% CAGR from 2024 to 2034, reaching a valuation of US$ 115.2 million in 2024.
The global KRAS inhibitor market is mostly driven by the increasing need for efficient therapies for malignancies with KRAS mutations. Since KRAS mutations are common in many tumors and have previously been difficult to target, there is a great chance to address medical gaps and enhance patient outcomes through the discovery of effective inhibitors.
Request a Sample Copy of the Report Now. https://www.futuremarketinsights.com/reports/sample/rep-gb-19271
Combination therapies offer a possible possibility in the KRAS inhibitor industry. Companies can provide patients with KRAS-mutated tumors more comprehensive and individualized therapy choices by improving treatment effectiveness and overcoming resistance mechanisms. Targeting several pathways at once or investigating synergistic effects with present medicines are two methods to do this.
Key Takeaways from the KRAS Inhibitor Market Analysis
- The global KRAS inhibitor market was estimated to reach US$ 81.8 million in 2019.
- Historically, from 2019 to 2023, the KRAS inhibitor market garnered a CAGR of 7.20%.
- The United States KRAS inhibitor ecosystem is anticipated to develop at a CAGR of 5.7% over the projection period.
- Through 2034, the application of KRAS inhibitors in the treatment of pancreatic cancer is expected to expand at a 5.3% CAGR.
- With a predicted 5.1% CAGR through 2034, cancer diagnostic centers are projected to be the primary end users of KRAS inhibitors.
“Market players can effectively use the KRAS inhibitors to enhance the treatment of lung cancer patients. They can effectively harbor the KRAS G12C mutant forms and thus reverse immunosuppression,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Competitive Landscape from the KRAS Inhibitor Market:
Market players within the KRAS inhibitor market are setting themselves apart with extensive clinical trial programs that demonstrate effectiveness in a range of cancer types. It includes metastatic colorectal cancer and non-small cell lung cancer.
They are also investigating new combinations with current treatments in an effort to improve treatment results for people with malignancies who have KRAS G12C mutations.
Startups in the KRAS inhibitor market are using novel approaches like structure-based drug design and computational biology to find and develop strong inhibitors of KRAS mutations.
They are also forming strategic alliances with academic institutions and biopharmaceutical companies to speed research and development activities. The startups are aimed at providing breakthrough medicines to patients suffering from KRAS-mutated malignancies.
Buy this Report Now: https://www.futuremarketinsights.com/checkout/19271
Key Development in the KRAS Inhibitor Market:
- In 2024, Erasca and Novartis signed into two clinical trial partnership and supply agreements. This is to assist the development of trametinib, an inhibitor of mitogen-activated protein kinase kinase (MEK), in conjunction with naporafenib for the treatment of cancer.
- Patients with rat sarcoma (RAS) Q61X solid tumors and previously treated NRAS-mutant melanoma are the targets of the SEACRAFT-1 and SEACRAFT-2 studies, respectively. The combination of naporafenib and trametinib will be evaluated in patients with RAS Q61X solid tumors as part of the Phase Ib SEACRAFT-1 study.
The Top Key Companies Profiled in the KRAS Inhibitor Market:
- Amgen
- Boehringer Ingelheim
- BridgeBio Pharma
- Erasca
- Innovent Biologics Inc.
- Incyte
- Mirati Therapeutics
- Novartis
- Jemincare
- Cardiff Oncology Inc.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the KRAS inhibitor market, providing historical data for 2019 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the KRAS inhibitor market, the market is segmented on the basis of cancer type (lung cancer, pancreatic cancer, colorectal cancer, others), end user (clinic laboratories, cancer diagnostic centres, hospitals, cancer research institutes, academic institutions, others) and region (North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, Middle East & Africa).
Click Here to Request Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-19271
Key Segments Profiled in the KRAS Inhibitor Market:
By Cancer Type:
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
By End User:
- Clinic Laboratories
- Cancer Diagnostic Centres
- Hospitals
- Cancer Research Institutes
- Academic Institutions
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East & Africa
About the Healthcare Domain at Future Market Insights
The healthcare domain at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with the objective of providing authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 billion+ data points, the team has been analyzing the market lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at the Latest Report from the KRAS Inhibitor Market:
PARP Inhibitor Market size is expected to reach US$ 6,279.90 million in 2024, at a CAGR of 8.70% through 2034. The industry value is likely to reach US$ 16,153.50 million by 2034.
Isocitrate Dehydrogenase (IDH) Inhibitors Market garnered a market value of US$ 1.7 Billion in 2022 and is expected to accumulate a market value of US$ 39.16 Billion by registering a CAGR of 33% in the forecast period 2023 to 2033.
Kinase Inhibitors For Cancer Treatment Market is expected to reach a valuation of US$ 122,133.64 million by 2032. The market is valued at US$ 45,000 million as of 2022 and is anticipated to grow at a CAGR of 10.5% during the forecast.
Inhalation And Nasal Spray Generic Drugs Market is US$ 20.78 Billion in 2023. The value of the inhalation and nasal spray generic drugs market is anticipated to reach a high of US$ 49.01 by the year 2033.
Inhalation CDMO Market is expected to expand at a CAGR of 5.7% in the forecast period 2024 to 2034. The market value is projected to increase from US$ 8,639.1 million in 2024 to US$ 14,863.6 million in 2034.
Inhalation Formulation Market is expected to rise from US$ 41,831.2 million in 2024 to US$ 60,157.2 million by 2034. By 2034, the market is projected to surge at 3.7% CAGR.
Respiratory Inhaler Devices Market size is anticipated to attain an impressive valuation of US$ 37,258.5 million in 2023 and is projected to reach US$ 60,114.7 million by 2033, trailing a CAGR of 4.90% during the forecast period.
Inhaled Nitric Oxide Delivery Systems Market is expected to reach a worth of about US$ 735.7 million by the end of 2032, with a projected CAGR of 9.5% from 2022 to 2032.
Dry Powder Inhaler Market is projected to be worth US$ 20.83 billion in 2024. The market is likely to reach US$ 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from 2024 to 2034.
Metered Dose Inhalers Market in 2022 was US$ 25,208.9 million and is estimated to be US$ 26,322.9 million in 2023.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
